 |
2009
OMIG, Abstract 23
OMIG Main Page | 2009 Abstracts | < Previous| Next >
A Combination Povidone-Iodine 0.4% / Dexamethasone 0.1% Ophthalmic Suspension in the Treatment Of Adenoviral Conjunctivitis.
J.S. Pelletier1, K. Stewart1, W. Trattler2, D.C. Ritterband3,4, S. Braverman5, C.M. Samson3,4,6, B. Liang6, J.A. Capriotti1,6
1Ocean Ophthalmology Group, North Miami Beach, FL, 2The Center For Excellence in Eye Care, Miami, FL, 3New York Eye and Ear Infirmary, New York, NY, 4New York Medical College, Valhalla, NY, 5Braverman Eye Center, Hallandale Beach, FL, 6CLS Pharmaceuticals, New York, NY
Purpose: The objective of this pilot study was to determine the efficacy of an ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% in the treatment of adenoviral conjunctivitis.
Methods: Eligible patients who tested positive for adenoviral antigen by RPS Adeno Detector® were enrolled in a single treatment arm consisting of a combination povidone-iodine / dexamethasone ophthalmic suspension given 4 times daily for a minimum of 5 days. RPS Adeno Detector® testing was performed at baseline and at each follow-up visit along with ocular fluid sampling by conjunctival swabs. Subsequent analysis performed on all swabs included both adenoviral titer by qPCR and CC-IFA. The primary endpoint was clinical resolution of conjunctival injection and discharge. Secondary measures included qPCR titers and CC-IFA results.
Results: A total of 9 eyes of 6 patients with clinical signs and symptoms of acute viral conjunctivitis and a positive RPS Adeno Detector® test result were enrolled in the study. In 8/9 eyes enrolled in the study, clinical resolution was observed by Day 4. In 6/6 eyes with detectable adenovirus by qPCR, significant reduction in viral titer was seen by Day 3, Day 4 or Day 5. In 5/6 eyes with infectious virus confirmed by CC-IFA at enrollment, elimination of infectivity was achieved by Day 4 or Day 5. One patient was lost to follow-up.
Conclusions: An ophthalmic suspension containing povidone-iodine 0.4% and dexamethasone 0.1% may be a useful agent in the treatment of acute RPS Adeno Detector® positive conjunctivitis.
This work was supported by a grant from Foresight Biotherapeutics.
|
 |
|
